BPUR.
I think thas it´s going to fly to 1$.Notice.
Biopure Announces Closing of $11.3 Million FinancingMonday January 10, 4:05 pm ET
CAMBRIDGE, Mass., Jan. 10 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today the closing of a previously announced financing that raised $11.3 million, for net proceeds to Biopure of $10.4 million. Biopure sold 22.2 million shares of its common stock at $0.51 per share to institutional and individual investors. C.E. Unterberg, Towbin, LLC acted as the agent for the offering.
Biopure Corporation develops and manufactures intravenously administered pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's tissues. The company is developing Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia and, in collaboration with the U.S. Naval Medical Research Center, for an out- of-hospital trauma indication. The product is approved in South Africa for treating surgery patients who are acutely anemic and for eliminating, delaying or reducing allogeneic red blood cell transfusions in these patients. Biopure's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
CAMBRIDGE, Mass., Jan. 10 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR - News) announced today the closing of a previously announced financing that raised $11.3 million, for net proceeds to Biopure of $10.4 million. Biopure sold 22.2 million shares of its common stock at $0.51 per share to institutional and individual investors. C.E. Unterberg, Towbin, LLC acted as the agent for the offering.
Biopure Corporation develops and manufactures intravenously administered pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's tissues. The company is developing Hemopure® [hemoglobin glutamer - 250 (bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia and, in collaboration with the U.S. Naval Medical Research Center, for an out- of-hospital trauma indication. The product is approved in South Africa for treating surgery patients who are acutely anemic and for eliminating, delaying or reducing allogeneic red blood cell transfusions in these patients. Biopure's veterinary product Oxyglobin® [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs.
posted by Juan Dosil @ 3:04 AM
0 Comments:
Post a Comment
<< Home